Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Alpine Immune Sciences advances drug pipeline amidst financial challenges

Alpine Immune Sciences shows promise with progress on povetacicept and strategic studies for autoimmune diseases.
While facing financial challenges, the company's strong cash position and collaborations offer growth opportunities.
Effective cost management, successful clinical trials, and market expansion are crucial for Alpine's future success.

Alpine Immune Sciences reports robust 2023 performance and clinical advancements

Alpine Immune Sciences demonstrated strong financial performance and promising clinical advancements in 2023.
The company's focus on povetacicept as a disease-modifying therapy presents significant opportunities for growth.
Challenges lie in maintaining clinical momentum and managing expenses effectively to sustain progress.
Overall, Alpine's strategic initiatives position it well for continued success in the biopharmaceutical space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Vertex Pharmaceuticals

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. Th.

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Alpine Immune Sciences (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alpine Immune Sciences, Inc. (NasdaqGM: ALPN) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Alpine will receive $65.00 in cash for each share of Alpine that they own. KSF is seeking to determine whether this consideration and the process t.

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN

NEW YORK , April 17, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Alpine Immune Sciences, Inc. (Nasdaq: ALPN), relating to its proposed sale to Vertex Pharmaceuticals Inc..

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPN

Entera Bio Ltd

Rezolute

Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

Vera Therapeutics

The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.

2 Biotech Stocks Driving the Nasdaq Today

The acquisition is a bet on a drug under development to treat the kidney condition IgA nephropathy.

Vertex Pharmaceuticals to Buy Alpine Immune in $4.9B Deal

Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It

Drug maker Alpine Immune Sciences (NASDAQ: ALPN ) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ: VRTX ) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial.

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?

Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)

Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.

Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio

Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.

Alpine Immune Sciences soars on $4.9bn Vertex takeover

Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.

Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch

MILWAUKEE , April 10, 2024 /PRNewswire/ -- Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vertex. Click here to learn how to join the https://www.ademilaw.com/case/alpine-immune-sciences-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex

Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.

Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders. Halper Sadeh encourages Alpine shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whe.

ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion

Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal

Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.

Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina. Povetacicept is a potent dual antagonist of the BAFF (B cell activating factor).

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Direct.

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

Alpine Immune Sciences (ALPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos.

Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024. Presentation Highlights Include: BAFF- and APRIL-related genes are increased in myeloid and B cells in systemic lupus er.

News for Alpine Immune Sciences Stock (ALPN)